Zura Bio (NASDAQ:ZURA - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.05), FiscalAI reports.
Zura Bio Stock Down 7.2%
NASDAQ ZURA traded down $0.35 during trading hours on Thursday, hitting $4.54. 976,506 shares of the stock were exchanged, compared to its average volume of 627,273. The company has a market cap of $430.76 million, a price-to-earnings ratio of -4.28 and a beta of 0.09. Zura Bio has a 12-month low of $0.98 and a 12-month high of $7.44. The stock has a 50-day moving average of $5.94 and a 200 day moving average of $5.16.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on ZURA. Oppenheimer decreased their target price on Zura Bio from $16.00 to $15.00 and set an "outperform" rating for the company in a research report on Friday, March 20th. Wedbush began coverage on shares of Zura Bio in a research report on Monday, February 9th. They issued an "outperform" rating and a $15.00 price target for the company. Chardan Capital raised their price objective on shares of Zura Bio from $10.00 to $11.00 and gave the stock a "buy" rating in a research report on Monday, March 23rd. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Zura Bio in a report on Wednesday, April 8th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $10.75.
Read Our Latest Research Report on ZURA
Insider Activity at Zura Bio
In other Zura Bio news, major shareholder Ai Biotechnology Llc purchased 2,000,000 shares of the firm's stock in a transaction that occurred on Thursday, February 26th. The shares were purchased at an average cost of $6.25 per share, for a total transaction of $12,500,000.00. Following the completion of the purchase, the insider directly owned 6,552,725 shares in the company, valued at $40,954,531.25. This represents a 43.93% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 14.23% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Zura Bio
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. grew its position in Zura Bio by 78.7% during the second quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company's stock worth $4,893,000 after buying an additional 2,052,732 shares during the period. Siren L.L.C. purchased a new position in Zura Bio in the 4th quarter valued at approximately $6,812,000. VR Adviser LLC raised its holdings in Zura Bio by 15.4% during the fourth quarter. VR Adviser LLC now owns 5,345,115 shares of the company's stock worth $28,008,000 after purchasing an additional 713,899 shares during the last quarter. Braidwell LP boosted its position in Zura Bio by 28.6% during the fourth quarter. Braidwell LP now owns 3,180,389 shares of the company's stock worth $16,665,000 after purchasing an additional 707,583 shares in the last quarter. Finally, Marshall Wace LLP grew its holdings in Zura Bio by 228.5% in the fourth quarter. Marshall Wace LLP now owns 877,763 shares of the company's stock valued at $4,599,000 after purchasing an additional 610,563 shares during the last quarter. 61.14% of the stock is owned by institutional investors and hedge funds.
Zura Bio Company Profile
(
Get Free Report)
Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.
The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zura Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zura Bio wasn't on the list.
While Zura Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
